Roth Capital Maintains Buy on VirTra, Raises Price Target to $13

Roth Capital maintains VirTra (NASDAQ:VTSI) with a Buy and raises the price target from $10 to $13.

byBenzinga Newsdesk

August 13, 2021

1 minute read

Roth Capital maintains VirTra (NASDAQ:VTSI) with a Buy and raises the price target from $10 to $13.

Leidos Awarded DARPA Contract With Total Ceiling Value Of $19.3M To ‘Develop Advanced Protective Equipment For U.S. Military’

By Benzinga Newsdesk

Today, 6:38 AM

Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a prime contract by Defense Advanced Research Projects Agency (DARPA) for their Personalized Protective Biosystem

LDOS

Ethereum L2 Coins Like Polygon (MATIC) Having A Rough Year While L1s Walk Toe-To-Toe, Says Research

By Shivdeep Dhaliwal

Today, 6:38 AM

Layer 2 tokens remain underdogs in 2022 as the spotlight was stolen by Layer 1 coins, according to a note from Kaiko Research.

$MATIC

BioNTech Announces Strategic Partnership With U.K. Government To Provide Up To 10,000 Patients With Personalized mRNA Cancer Immunotherapies By 2030

By Benzinga Newsdesk

Today, 6:38 AM

Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech's footprint in the UK BioNTech aims to design and roll out randomized

BNTX

Tesla Top-Discussed Stock On WallStreetBets Heading Into New Week; GameStop, Nio, Nvidia And These Are Other Top Trends

By Madhukumar Warrier

Today, 6:38 AM

Tesla Inc. (NASDAQ: TSLA) has emerged as the most-discussed stock on Reddit’s r/WallStreetBets forum as of early Monday, while GameStop Corp.

CLF

Roth Capital Maintains Buy on VirTra, Raises Price Target to $13

Related Posts

Leidos Awarded DARPA Contract With Total Ceiling Value Of $19.3M To ‘Develop Advanced Protective Equipment For U.S. Military’

Ethereum L2 Coins Like Polygon (MATIC) Having A Rough Year While L1s Walk Toe-To-Toe, Says Research

BioNTech Announces Strategic Partnership With U.K. Government To Provide Up To 10,000 Patients With Personalized mRNA Cancer Immunotherapies By 2030

Tesla Top-Discussed Stock On WallStreetBets Heading Into New Week; GameStop, Nio, Nvidia And These Are Other Top Trends